News Focus
News Focus
Followers 57
Posts 9801
Boards Moderated 0
Alias Born 09/02/2006

Re: Doc328 post# 466329

Sunday, 08/04/2024 1:56:33 PM

Sunday, August 04, 2024 1:56:33 PM

Post# of 517109
Dox328...thanks!
I don't qualify to judge because all of this is way above my head, but I do consider you to be more informed than most who post here...

I did notice some problems with "Conflicts of Interest" especially for fees names like Acadia, Biogen, Elsai, and grants from those names and others

Conflict of interest statement
AP reports personal fees from Acadia Pharmaceuticals, Alzheon, Avanir, Biogen, Cadent Therapeutics, Eisai, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, and Syneos; grants from Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, and Vaccinex. RI has nothing to disclose. MS reports personal fees from Alzheon, Athira, Biogen, Cortexyme, Danone, Neurotrope, Regeneron, Roche-Genentech, and Stage 2 Innovations; stock options from Brain Health Inc, NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, and Versanum Inc. Additionally, he has intellectual property rights with Harper Collins. SK and IR report employment with Biogen.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News